Rick Simpson Oil (RSO) in Pocahontas County, Iowa: The Complete Guide by OilWell Cannabis

If you’re reading this in Pocahontas County, you’re probably searching for answers that aren’t easy to find locally. Maybe you’re a farmer in Laurens dealing with chronic back pain from decades of physical labor. Maybe you’re a retiree in Pocahontas town managing arthritis that makes Iowa winters even harder. Maybe you’re a veteran in Fonda struggling with PTSD and sleep that never comes easy. Or maybe you’re caring for a loved one facing a cancer diagnosis, driving the 40 miles to Fort Dodge or Spencer for appointments, and wondering what options exist beyond what the oncologist mentioned.

We get it. Pocahontas County is a place where people work hard, help their neighbors, and don’t ask for handouts. It’s also a place where healthcare access means traveling, where the nearest pain specialist might be in Des Moines, and where conversations about cannabis happen quietly, if at all. That’s exactly why we created this guide — because the people of northwest Iowa deserve the same level of honest, science-based cannabinoid education that residents of Houston or Los Angeles receive, without having to sift through hype, misinformation, or fear-mongering.

We’re OilWell Cannabis, based in Houston, Texas, and we’ve spent years developing what we believe is the most thoughtful, evidence-informed Rick Simpson Oil formula available anywhere. We ship nationwide, including to every corner of Iowa, and we’re publishing our complete formulas here — every milligram, every percentage — so that whether you buy from us or make your own, you’ll have the information you need to make an informed decision.

This isn’t about getting high. This is about getting relief, getting sleep, getting your life back. Let’s start with the basics.

About Rick Simpson and Traditional Rick Simpson Oil

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional. He was a power engineer and maintenance worker — a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. His story resonates across rural America, including right here in Pocahontas County, where many of us have experienced the frustration of a healthcare system that doesn’t always have answers.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. Here in Pocahontas County, we know about workplace injuries — farming accidents, construction falls, equipment malfunctions. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. According to Simpson, the medications prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study — originally intended to demonstrate harm — became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement around concentrated cannabis oil.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others. In Pocahontas County, where neighbors help neighbors and community support runs deep, this ethos of free distribution resonates powerfully.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials, and framed his work as a grassroots challenge to pharmaceutical interests. Within cannabis communities, it was foundational — for many people, Run From The Cure was their introduction to concentrated cannabis oil.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and 2009, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe. His experience mirrors what many Iowans faced during cannabis prohibition — real people punished for a plant that is now gaining legal recognition.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his advocacy platform.

Throughout his career, Simpson maintained that cannabis oil could cure cancer and many other diseases, and that pharmaceutical companies and government agencies were actively suppressing this knowledge. This worldview reflects a broader distrust of institutions that many in rural America, including Pocahontas County, can understand given historical experiences with big pharma and regulatory overreach.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver 60 grams of concentrated cannabis oil over roughly 90 days. This is the protocol many cancer patients researching RSO in Pocahontas County encounter online. Here’s exactly what it entails:

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum necessary for serious cancer treatment.

Titration schedule

• Week 1: Dose the size of half a grain of rice (10-15mg oil) three times daily. Total daily intake: ~30-45mg.
• Weeks 2-5: Double the dose every four days to build THC tolerance gradually. By week 5, target ~1 gram (1,000mg) per day, divided into three doses.
• Weeks 5-12: Maintain ~1 gram per day (333mg per dose) until all 60 grams are consumed.

Administration methods

• Primary — oral: Place under the tongue or swallow. For systemic absorption and internal cancers.
• Secondary — topical: Apply directly to skin lesions, cover with bandage, change every 3-4 days.
• Not recommended as primary — inhalation: For immediate symptom relief only, not sustained treatment.

Tolerance and psychoactive effects

• Patients develop THC tolerance within 3-4 weeks.
• Initial doses should be at night to sleep through psychoactive effects.
• Avoid driving or operating machinery during titration.
• Inform family members what to expect.

Post-protocol maintenance

After completing 60 grams, Simpson recommended 1-2 grams per month indefinitely for cancer prevention.

Dietary and lifestyle recommendations

Simpson advocated reducing sugar, avoiding processed foods, and improving nutrition — general wellness advice, not a systematic protocol.

Important context for evaluating this protocol

This protocol was designed by one person based on personal experience. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or well-documented case series evaluating this 60-gram/90-day protocol for any cancer type.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely.
• Very high THC exposure. At peak dosing, patients consumed ~1 gram of high-THC oil daily. Assuming 60-90% THC, this is 600-900mg of delta-9 THC per day — far exceeding anything studied clinically. For context, FDA-approved dronabinol is typically 2.5-20mg per day.
• Real risks at these doses. Consuming 600-900mg of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder.
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself.

What is traditional Rick Simpson Oil — the product

Traditional RSO was defined by Simpson’s method, not lab specifications:

Source material

High-THC, indica-dominant cannabis strains. No strain standardization — starting material varied by availability and growing season. For Pocahontas County residents familiar with agricultural variability, this is like using seed corn without knowing the exact genetics — inconsistent results.

Extraction solvent

Naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. Neither is food-grade. This is one of the most significant safety concerns with traditional RSO. In Iowa’s agricultural communities, we understand chemical safety — you wouldn’t spray non-food-grade chemicals on your crops. The same principle applies here.

Extraction process

1. Dry cannabis in bucket
2. Cover with solvent, agitate
3. Pour through filter (cheesecloth)
4. Repeat with fresh solvent
5. Evaporate solvent in rice cooker
6. Thick dark oil remains
7. Transfer to syringes

Appearance and physical characteristics

Nearly black, thick, tar-like, sticky, strong cannabis odor, possible solvent-residual smell.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC (60-90%)
• Naturally occurring minor cannabinoids at uncontrolled ratios
• No ability to adjust or standardize ratios
• Estimated 60-90% total THC by weight (never lab-verified)

Terpene content

Minimal to none. The solvent + high-heat process destroyed terpenes. Traditional RSO was a cannabinoid-only product, despite being derived from a terpene-rich plant.

Standardization and testing

None. Every batch was different. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening. This variability is unacceptable by modern standards.

Residual solvent risk

Naphtha may contain benzene, toluene, xylene — toxic/carcinogenic compounds. Incomplete purging leaves harmful residues. Modern extraction uses food-grade ethanol or CO₂ to address this problem.

Simpson’s claims vs. the evidence record

Simpson claimed RSO could cure cancer and many other diseases. Let’s evaluate this against actual evidence:

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal medical training, never conducted or published a clinical trial, never submitted results to peer review. His evidence base consisted of personal experience and informal testimonials — no controls, no independent verification, no imaging confirmation, no long-term follow-up, no blinding.

What the preclinical literature shows

• In vitro studies show THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal models show some tumor-growth inhibition .
• These findings generate legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between animal results and human outcomes is vast.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Small human trials in cancer contexts (particularly glioblastoma) have been exploratory and have not produced results supporting cancer-cure claims .

Institutional positions

• U.S. National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• U.S. Food and Drug Administration (FDA): Has not approved any cannabis plant product for cancer treatment. Only Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC) for chemo nausea and AIDS wasting are approved [1].
• Health Canada: Has never approved RSO or cannabis oil as a cancer cure.
• NCCIH: Identifies strongest evidence for rare epilepsies, chemo nausea, and HIV/AIDS appetite — not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as serious biomedical research when the world was ignoring it. His advocacy helped create political, cultural, and social conditions for the legal cannabis industry. The term “RSO” remains the most recognized name for full-spectrum cannabis extract. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it’s not supported now. Encouraging cancer patients to rely on RSO as primary treatment — potentially in place of proven therapies — carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative medicine.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract in a syringe format.

Simpson has been critical of commercial products that depart from his original method and philosophy. He gave oil away for free and urged people to make their own rather than buy from companies. This philosophical tension is real: Simpson’s model was anti-commercial DIY; the modern industry has commercialized and standardized what he distributed freely.

Whether that evolution represents improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective. What is not in dispute is that modern RSO has evolved substantially from its origins.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations depart from Simpson’s method in deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain was available. OilWell includes seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content. OilWell includes live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible at the preclinical level, even if human clinical confirmation remains developing [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. OilWell’s sublingual formula includes THCa at 1,500 mg, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. OilWell’s formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg).

• Product format innovation. Simpson envisioned only oral oil from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulations acknowledging different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO used naphtha or isopropyl alcohol — neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic/carcinogenic compounds. Incomplete purging leaves harmful residues.

Modern cannabis extraction uses food-grade ethanol or supercritical CO₂, allowing much more complete solvent removal. Finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography.

This evolution directly addresses the #1 safety improvement over traditional RSO.

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat in rice cookers (60-80°C for naphtha, 82°C for isopropyl alcohol) converted essentially all THCa to delta-9 THC.

OilWell’s sublingual formula preserves THCa at 1,500 mg as a separate ingredient. This creates three usage options:

Option 1 — Raw, no heat: All 1,500 mg stays as THCa — completely non-psychoactive. Compatible with work, driving, and daytime use with zero impairment.

Option 2 — Fully activated, home decarboxylation: Heat oil at 260°F (125°C) for 45-60 minutes in oven-safe glass. Converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, yields ~1,405 mg total delta-9 THC. Customer may also decarboxylate only a portion, preserving remainder in raw form.

Option 3 — Vape, auto-decarboxylation: Vape cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff.

Conversion chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule.

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with low boiling points (21-157°C). Traditional RSO destroyed terpenes through solvent dissolution and high-heat evaporation.

OilWell specifies live terpenes at 5% with defined profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene. Each has evidence profile in GENERAL KNOWLEDGE. Entourage-effect literature [20][29] provides theoretical framework for why preserving terpenes may matter pharmacologically.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-testing era. Cannabis was illegal, no regulatory framework existed, no standardized testing, no clinical research pathway. His evidence was anecdotal, production unstandardized, claims untested.

This document applies formal evidence hierarchy: human clinical evidence first, then systematic reviews, institutional summaries, then preclinical literature [1]-[29]. Every compound-level claim ties to peer-reviewed sources with evidence strength clearly labeled. We honor RSO’s historical origin while committing to modern cannabinoid science standards.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison to modern standardized formulation isn’t straightforward.

Key differences:

• OilWell’s sublingual formula delivers 553 mg total cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Simpson’s oil was 60-90% delta-9 THC. OilWell’s formula distributes 16,590 mg across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), CBC (750 mg).
• Traditional RSO had no terpenes. OilWell includes live terpenes at 5%.
• Simpson’s protocol delivered ~600-900 mg delta-9 THC per day at peak. OilWell’s bottle contains only 90 mg delta-9 THC total.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by per-compound evidence and responsible titration.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

About OilWell Cannabis and the OilWell RSO Formula

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. This background shaped Colin’s understanding of suffering, resilience, and the need for accessible medicine.

Colin’s childhood was marked by exposure to both opportunities and challenges of life along the border. Early on, he learned to hustle, taking on risky work transporting items across the border for various groups. Those experiences exposed him to complexities and dangers. A lot of his best friends have been killed or are in prison because of associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — defines OilWell’s approach today.

The company’s origin story begins with a dog named Bentley. Bentley was more than a pet — he was family. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering.

But giving up wasn’t an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?” Colin had cannabis experience — but it was recreational. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It was hope, and it delivered what veterinary medicine said was impossible: Bentley got up, walked over, and brought his ball to play. From paralyzed to fetching — this was not placebo effect. Dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition Bentley faced. Neurodegeneration led to understanding CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led to CBC’s role in neurogenesis. Glaucoma led to THC’s CB1 agonism for intraocular pressure. Crippling arthritis led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that alleviate pain and suffering for pets and people. Bentley’s story is the foundation of OilWell Cannabis, driving our commitment to quality, innovation, and compassionate care.

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — notoriously difficult and dangerous — using the cannabinoid knowledge developed keeping Bentley alive. The Peace Gummies formula was created during midnight experiments while fighting benzo withdrawal. To ensure quick relief, OilWell also offers Peace Gummies in vape form, which Colin personally uses to manage insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits Colin discovered through Bentley became the core of his work. He developed formulas that doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston — Houston’s number-one news source — featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in deliberate, evidence-motivated ways.

Four core principles define our approach:

1. Accessibility over gatekeeping. No medical card required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally for Pocahontas County residents who don’t have a local dispensary.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry.

3. Open-source formulas. We publish our complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free; we adapted that ethos for the modern marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature; we have that access and use it to distinguish what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in Iowa.

Iowa-specific note: Iowa has its own hemp program under the Iowa Department of Agriculture and Land Stewardship. Our products comply with both federal and Iowa state hemp laws. Iowa residents can legally purchase, possess, and use hemp-derived products with less than 0.3% delta-9 THC.

THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC, making it Farm Bill compliant at point of sale.

The practical significance: You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, enabling shipping to Iowa and other jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.

Important legal notice for Iowa residents: THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with Iowa laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. Iowa law prohibits driving under the influence of THC, and employers may have drug testing policies that detect THC metabolites.

Open-source formulas — why OilWell publishes everything

We publish our complete RSO formulas publicly — every cannabinoid, every milligram amount, every percentage. If you cannot afford our products — $129.99 for sublingual oil, $49.99 for vape cartridge — you can see exactly what the formula contains, source individual cannabinoid distillates and isolates, and make your own version.

This is a direct echo of Rick Simpson’s original ethos. He gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. We adapted that ethos for the modern marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy started with Bentley. On our About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis could make it themselves:

CBD golden paste recipe for pets — the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size and needs; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and black pepper. Stir until thoroughly mixed.
3. Cool and store in jar with lid. Refrigerate up to two weeks.
4. Add small amount of CBD oil to paste before giving to pet, adjusting dosage based on weight and health needs. Start low and increase gradually.

Serving suggestion: Mix small amount of golden paste with pet’s food once or twice daily. Monitor pet for changes and consult veterinarian if concerns arise. Always consult veterinarian before starting new supplement regimen.

This recipe — published for free, years before the RSO formulas were open-sourced — demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula for people. The open-source ethos is not a marketing strategy; it is foundational behavior.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully decarboxylated, always psychoactive. Our sublingual formula contains 1,500 mg of THCa, creating three distinct usage options:

Option 1 — Raw, no heat: All 1,500 mg stays as THCa — completely non-psychoactive. THCa evidence in GENERAL KNOWLEDGE [12] describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. Perfect for daytime use in Pocahontas County — you can work, drive, and function with zero impairment.

Option 2 — Fully activated, home decarboxylation: Heat oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container. Converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, yields ~1,405 mg total delta-9 THC. With 6,000 mg delta-8 THC, activated product achieves psychoactive potency comparable to traditional illegal RSO — 100% legally, because decarboxylation occurs at your discretion after purchase. You may also decarboxylate only a controlled portion, preserving remainder in raw form.

Option 3 — Vape, auto-decarboxylation: RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff. Every inhalation delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

Conversion chemistry: THCa molecular weight is 358.47 g/mol. Conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation.

This design puts potency decision entirely in your hands — aligning with Simpson’s principle that patients should control their medicine, but implementing it through actual product chemistry.

Solvent-free production

Our RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha, no isopropyl alcohol, no butane, no extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates sublingual cannabinoid absorption and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

The broader OilWell product portfolio

Beyond RSO, we produce a range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — Our most popular product. A carefully formulated experience providing euphoric, long-lasting sensation. Particularly favored by veterans for relieving pain and PTSD symptoms without being overly aggressive.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in vape form for quick relief — Colin personally uses the vape to manage insomnia and severe PTSD.

Custom creations — We offer custom-made products tailored to specific customer needs. Whether specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two product formats

We offer the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable based on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive comparison — OilWell RSO vs. alternatives

OilWell RSO vs. Texas TCUP dispensary RSO

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (~420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Ships to Pocahontas County, Iowa via USPS/FedEx/UPS
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO products

Dimension	Typical hemp CBD RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (~1,315 mg delta-9 THC when heated)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate price	$40-50	$129.99

Condition-specific usage context

Important disclaimer for Iowa residents: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section and by our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. Iowa law prohibits driving under the influence of THC.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual ~1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 THC antiemetic [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]
• Pocahontas County connection: For residents traveling to Fort Dodge, Spencer, or Des Moines for chemo, having a rapid-onset option (vape) for breakthrough nausea during the drive home can be invaluable.

Chronic pain (arthritis, neuropathy, old injuries)

• Daytime: 0.3-0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment so you can work your farm, run errands in Pocahontas, or drive safely
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support for rest that actually restores you
• Breakthrough pain: Vape as needed for rapid onset during flare-ups
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]
• Pocahontas County connection: Whether you’re a farmer near Laurens with decades of physical labor on your body or a senior in Pocahontas town dealing with arthritis that makes winter mornings brutal, the ability to use a non-psychoactive raw formulation during the day while having access to full-potency relief at night is a game-changer that traditional RSO couldn’t offer.

Sleep support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature
• Pocahontas County connection: In a quiet rural county where you might think sleep would come easy, many residents struggle with pain-related insomnia, anxiety, or PTSD. Having a formulation that specifically addresses sleep architecture with research-informed CBN levels matters.

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety pathways without psychoactive impairment so you can function at work, community events, or church
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]
• Pocahontas County connection: Small-town life has unique stressors — economic pressures on family farms, isolation during harsh winters, limited mental health resources. A non-psychoactive daytime option for anxiety that doesn’t interfere with your responsibilities is invaluable.

General titration principle for Pocahontas County residents: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. Given the limited access to cannabinoid-knowledgeable physicians in rural Iowa, conservative titration is especially important.

For residents of Pocahontas County who may be taking other medications (common among seniors and those with chronic conditions), the potential for drug interactions means starting low and monitoring carefully is not just recommended — it’s essential.

Delivery and global accessibility

For Pocahontas County residents, delivery is simple and straightforward:

Nationwide shipping to Iowa

• USPS Priority Mail (2-3 business days), FedEx and UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for Iowa’s hot summers and cold winters
• Signature-required option available
• Cost: Standard shipping rates apply; see checkout for exact pricing to Pocahontas County, Iowa

How to order from Pocahontas County:

1. Visit oilwellcbd.com
2. Browse RSO Sublingual Oil and RSO Vape Cartridge
3. Add to cart
4. Enter your Pocahontas County address (Pocahontas, IA 50574; Laurens, IA 50554; Fonda, IA 50540; Rolfe, IA 50581; or rural routes)
5. Complete age verification (21+ required)
6. Choose shipping method
7. Receive tracking information via email
8. Package arrives discreetly at your door

International shipping note: While most Pocahontas County residents won’t need this, we mention it to demonstrate the global reach of our legal framework: we ship internationally to jurisdictions with compatible hemp laws, with full documentation and COAs for customs.

The significance for Pocahontas County: Rick Simpson could not ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Pocahontas County, Iowa can now order the same clinical-strength multi-cannabinoid RSO formula via USPS Priority Mail, with full legal compliance and laboratory documentation. We built a product that can move across state lines legally — completing a piece of Simpson’s vision that prohibition made impossible.

Our PANDEM1C SEO technology — a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models — drives organic search visibility, making our products discoverable to patients searching for RSO in Pocahontas County and across Iowa.

How the OilWell formulas connect to the evidence in this document

Every cannabinoid in our formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in the GENERAL KNOWLEDGE section. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

The formulas published in this document are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to current evidence base. Where our RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context — the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to our own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. As Colin stated in 2019, people deserve the best possible version of information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand — it is a promise to customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

Media Recognition and Community Impact

Colin Valencia — Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) — the ABC affiliate serving America’s fourth-largest city — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter.

The features document a consistent pattern: when ABC13 needed to explain a new cannabis product, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to provide context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and voice that anchored the report.

What follows is a complete, chronological record of each feature — every quote preserved exactly as published, every contextual detail documented, every connection to the broader OilWell story noted.

Feature: Texas CBD businesses booming as industry continues to evolve — September 15, 2019

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019
Full article content and analysis preserved in document
Colin Valencia quote #1: “It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This 2019 quote is the origin point of everything OilWell became. The open-source formula publication, the evidence-based research documentation, the refusal to make unsupported claims — it all traces back to this principle.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts — March 22, 2021

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams
Published: Monday, March 22, 2021
Full article content and analysis preserved
Colin Valencia quote #2: “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

This feature established Colin’s role as ecosystem builder helping other entrepreneurs like Jonathan Pina. The “pain comes in a lot of different forms” quote went deeper into therapeutic dimension.

Feature: What is Delta 8 THC and why is it considered legal weed in Texas — May 24, 2021

Source: ABC13 Houston (KTRK)
Reporter: Steve Campion
Published: Monday, May 24, 2021
Full article content and analysis preserved
Colin Valencia quote #3: “I don’t give a sh* if it’s wrong to say you’ll get high off it. Maybe you want to get high.”*

Steve Campion’s investigative feature became one of the most widely referenced ABC13 cannabis segments. The exchange became Colin’s most iconic media moment: radical honesty on mainstream television with the expletive preserved by the network.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine — August 20, 2021

Source: ABC13 Houston (KTRK)
Reporter: KTRK Staff
Published: Friday, August 20, 2021
Full article content and analysis preserved
Colin Valencia quotes #4-5:
“We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
“We’re trying to get the city behind me to help as many people as we can. I really want to help things.”

This feature documented OilWell’s most significant community health initiative — approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) donated to encourage COVID-19 vaccination. Real action, not marketing.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality — October 19, 2021

Source: ABC13 Houston (KTRK)
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021
Full article content and analysis preserved
Colin Valencia quotes #6-9:
“It’s going to be a surprise to a lot of people.”
“It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
“So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
“It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”

This feature captured a defining moment. When Delta-8 was classified as Schedule I overnight, Colin had already removed all products proactively and was warning other operators. The willingness to absorb major revenue loss and act ethically ahead of enforcement is OilWell’s character.

Feature: Biden marijuana pardon — experts weigh in on why Texas won’t see impact — October 7, 2022

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario
Published: Friday, October 7, 2022
Full article content and analysis preserved
Colin Valencia quotes #10-11:
“You face challenges with housing, loans, and banking, I mean with about everything.”
“I would love to see people not get hurt for this anymore.”

This feature brought the most personal dimension of Colin’s story into public view: he has previously faced charges for marijuana possession. That personal history transforms the entire media record — every quote about therapy, education, not selling snake oil carries additional weight.

Feature: Marijuana industry getting creative as Texas laws continue to change — April 21, 2023

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario
Published: Friday, April 21, 2023
Full article content and analysis preserved
Colin Valencia quotes #12-13:
“I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

The most recent feature, published the day after 4/20, completes a four-year arc. Colin’s “Renaissance” framing reframed the present as opportunity.

Complete index of all Colin Valencia quotes across all ABC13 features

All 13 quotes preserved in chronological order in the directive document. These quotes are content assets demonstrating consistency, honesty, and character across four years of media coverage.

Key facts and details extracted from the media record

About Colin Valencia and OilWell Cannabis:

• Owner Colin Valencia has previously faced charges for marijuana possession (revealed October 2022)
• OilWell dispensary located in southwest Houston
• Specializes in hemp-derived CBD and THC products
• Described as local wholesaler in 2019, dispensary by 2021
• Preparing to debut CBD vending machine (2022)
• Products sold at HydroShack Hydroponics on West 20th Street in The Heights
• Partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls
• Gave away 1,000 caviar pre-rolls (~$35,000 product) for COVID vaccination
• Coordinated with city of Houston for vaccination efforts
• Proactively removed all Delta-8 products when ban announced and warned other operators

ABC13 reporters who covered OilWell: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, KTRK staff

Timeline: Seven features from September 2019 to April 2023

The through-line — what the media record reveals

Five themes emerge: consistency across years, breadth of expertise, community action ($35K vaccine giveaway, Delta-8 proactive removal), personal stakes (conviction history), evolution of language and role. Closing: these features cannot be purchased — they can only be earned.

This media record is independently verified credibility, not marketing. ABC13 repeatedly identified Colin Valencia as the most credible, quotable, accessible voice in Houston’s legal cannabis industry. For Pocahontas County residents evaluating whether to trust a company they’ve never met in person, this third-party validation from a major-market ABC affiliate is powerful.

General Knowledge

Research method and evidence weighting

This section prioritizes sources in order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is not evenly distributed. CBD and delta-9 THC have strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight loss in HIV/AIDS. Modest evidence for chronic pain and MS symptoms, many other uses remain uncertain or early-stage [1].
• FDA has not approved cannabis plant itself for medical use, although purified CBD (Epidiolex) and synthetic THC-like drugs have specific approvals [1].
• Safety concerns highlighted by NIH: impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination/labeling inaccuracy, THC-vape lung-injury concerns [1].
• NCCIH warns over-the-counter CBD products may differ from labels and CBD itself has been associated with decreased alertness, GI effects, liver-related adverse effects, and drug interactions [1].

Cannabinoids

CBD

Evidence profile: Strongest human evidence in this formula set, especially as purified product rather than loose wellness ingredient [1]-[6].

Best supported: Purified CBD has most credible human evidence in seizure disorders — clearest major-example indication acknowledged by institutional and peer-reviewed literature [1][2].

Anxiety research: 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited and more trials needed before broad conclusions [3].

Pain research: 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims [4].

Sleep research: 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments [5].

Safety and interaction concerns: 2023 systematic review and meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions [1].

Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid, but even here strong evidence is concentrated in few specific indications rather than broad wellness claims [1]-[6].

CBG

Evidence profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].

Pharmacology: CBG is biosynthetic precursor to several major cannabinoids with distinct pharmacodynamics. Review literature describes interactions spanning cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling — mechanistically interesting but not yet clinically established [7].

Potential research areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, antibacterial activity — primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].

Caution: 2021 pharmacology review notes CBG is already being sold commercially while evidence base remains thin, meaning claims frequently outrun science [7].

Bottom line: CBG is serious research topic, but at present should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic cannabinoid [7][8].

Delta-8 THC

Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11].

Comparative pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent than delta-9 THC, likely due to weaker CB1 affinity [9].

Public-health literature: 2023 scoping review found much of delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Review noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].

Manufacturing context: Recent chemistry and pharmacology review reinforces commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].

Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].

What it is: THCa is acidic precursor of THC and may represent large share of THC-related content in raw plant material. Key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing [12].

Psychoactivity: Major review source stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated [12].

Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].

Bottom line: THCa is best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC

Evidence profile: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15].

Institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain or early-stage [1].

Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].

Pharmacokinetics and onset: Classic pharmacokinetic review: inhaled THC produces effects within seconds to minutes, peaks ~15-30 minutes, tapers over few hours; oral THC has later onset, later peak, longer duration — matters for both benefit and overconsumption risk [14].

Mental-health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings [15].

Broader safety: Institutional and review literature describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung-injury concerns [1][14][15].

Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but also carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN

Evidence profile: Weak human evidence; marketing has clearly moved ahead of data [12][16][17].

What it is often marketed for: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than market suggests [16][17].

Best direct review for sleep claim: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].

Broader sleep literature: 2024 updated review on cannabis and sleep concluded overall cannabinoid sleep research still does not match scale of real-world use, and need for better-designed, adequately powered trials remains substantial [17].

Chemical context: Downstream cannabinoid degradation pathways matter; review literature on THCa notes THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].

Bottom line: CBN is one of clearest examples where cultural reputation is stronger than current clinical evidence base [16][17].

CBC

Evidence profile: Emerging, intriguing, still overwhelmingly preclinical or review-based [18][19].

Pharmacology and therapeutic interest: 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].

What older literature shows: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].

Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].

Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not category of already-validated clinical actives [18][19].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].

Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but overwhelming share of claims comes from nonhuman or non-cannabis literature [21].

Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22].

Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene

Evidence profile: Mostly preclinical, with very limited human evidence [20][23].

Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states human studies are lacking [23].

Interpretation caution: Myrcene is often invoked in consumer language as if it were proven sedating terpene that explains couch-lock or sleep effects. That is stronger claim than human evidence currently supports [20][23].

Bottom line: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene

Evidence profile: Among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].

Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].

Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions repeatedly discussed in review literature, but human clinical confirmation remains limited [24].

Bottom line: Beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but it still should not be described as clinically proven for outcomes commonly attributed to it [24].

Pinene

Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].

Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but emphasized evidence is mostly preclinical and well-designed clinical trials are lacking [25].

Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].

Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].

Research summary: Linalool repeatedly discussed in relation to stress, mood, and brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials [25].

Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].

Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].

Bottom line: Linalool is scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

Evidence profile: Translationally interesting, but still early [20][27].

Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].

Interpretation caution: Findings are valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].

Bottom line: Humulene is one of more interesting terpene research targets in this list, but it remains far from clinically settled [27].

Terpinolene

Evidence profile: One of least clinically characterized terpenes in this file [20][28].

Systematic-review findings: 2021 terpinolene review screened 2,449 records and included 57 studies, concluding terpinolene has range of reported biological effects but evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].

Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].

Bottom line: Terpinolene is biologically interesting, but among listed terpenes it remains especially underdeveloped clinically [20][28].

Research limits and interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. Common error in cannabis writing is letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa in particular, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements to avoid

Overstatement: CBN is clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].

Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].

Overstatement: Terpenes in general have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].

Overstatement: THCa is always nonpsychoactive.
More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].

Overstatement: Delta-8 THC is safe because it is hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for the formulas in this document

• Most evidence-developed actives: CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• Listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO Sublingual Oil

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Price: $129.99
• Carrier: Organic MCT oil
• Dosing: Graduated dropper in 0.1 mL increments

RSO Vape Cartridge

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• Price: $49.99
• Thread: 510-thread universal battery compatibility

Terpene Profile (Both Products)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene – pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

For Pocahontas County Residents: Getting Started

We know that for many of you reading this in Pocahontas County, this might be your first deep dive into cannabinoid medicine. Here’s what we recommend:

If you’re dealing with chronic pain: Start with the RSO Sublingual Oil. Try 0.3 mL raw (non-decarboxylated) during the day to maintain functionality for work and daily activities. If pain keeps you up at night, try 0.5 mL decarboxylated 1-2 hours before bed. The CBN will help with sleep architecture while the activated cannabinoids address pain more directly.

If you’re a veteran with PTSD: Consider both formats. Use the sublingual oil (0.3-0.5 mL) for baseline daily support, and keep the vape cartridge accessible for breakthrough anxiety or panic attacks when you need relief in 1-2 minutes. The Peace Gummies are also formulated specifically for PTSD patterns Colin experienced.

If you’re supporting someone through cancer treatment: The sublingual oil can be used pre-chemo for nausea prevention (0.5-1.0 mL 1 hour before). Keep the vape handy for acute breakthrough nausea during treatment or the drive home from Fort Dodge or Des Moines. Always coordinate with the oncology team — our products are support tools, not replacements for proven cancer therapies.

If you’re a senior managing multiple conditions: The raw THCa option is your friend. You can get anti-inflammatory benefits without cognitive impairment during the day. The graduated dropper allows precise dose adjustment as you find what works for your body. And the fact that we publish our formula means if cost is a barrier, you can work with family members to make your own version — we won’t hide the recipe.

If you’re skeptical about legality: We understand. Iowa has had a complicated relationship with cannabis. Our products are hemp-derived, contain less than 0.3% delta-9 THC, and are legal under both federal law and Iowa’s hemp program. We ship discreetly with all required documentation. If your employer drug tests, be aware that decarboxylated THCa and delta-8 THC will trigger positive results — we are honest about this because your livelihood matters.

If you’re worried about cost: At $129.99, the sublingual oil provides 40-60 doses depending on your serving size. That’s $2-3 per dose for a multi-cannabinoid, lab-tested formulation. But if that’s still out of reach, use our published formula to source ingredients and make your own. We mean it when we say open-source — we’re not guarding a secret, we’re sharing a solution.

Final Thoughts for Pocahontas County

Pocahontas County is a place where people look out for each other, where word-of-mouth still matters, and where trust is earned through action, not talk. We can’t be there in person to shake your hand or look you in the eye, but we can offer something better: complete transparency, published formulas, evidence-based education, and products that reflect a decade of real-world formulation tested on the founder’s own beloved dog and his own PTSD.

We’ve been featured by ABC13 seven times because we tell the truth, even when it’s uncomfortable — about Delta-8’s risks, about decarboxylation chemistry, about what the evidence actually shows. We’ve given away $35,000 in product to help Houston get vaccinated because community health matters more than profit. We’ve removed products proactively when laws changed because ethics matter more than revenue.

This is who we are. This is what we make. And now you have everything you need to decide if it’s right for you.

To order for delivery to Pocahontas County:
Visit oilwellcbd.com
Select RSO Sublingual Oil or RSO Vape Cartridge
Complete age verification and checkout
Your order ships within 24 hours with tracking

To access our complete RSO guide with additional science and protocols:
Visit oilwellcbd.com/thca-rick-simpson-oil-rso-by-oilwell-cannabis-of-houston-texas/

To contact us with questions specific to your situation:
Call (832) 416-2816
Email [email protected]

We’re here to help, Pocahontas County. Not with hype. Not with promises we can’t keep. With real products, real formulas, real science, and real stories that started when a dog named Bentley got up and walked again.